Association Between Expression of Cancer Stem Cell Markers and Poor Differentiation of Hepatocellular Carcinoma

Li, Rui; Shen, Yuan; Kang, Nan; Mi, Baibing; Wu, Tao; Guo, Jinyue; Li, Miaojing; Lv, Yi; Guo, Hui

doi:10.1097/md.0000000000001306

Cited by 31 publications

(24 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liu et al [29] indicated that CD90 might be more sensitive in predicting poor differentiation in HCC. Cheng et al [30] found that CD90 probably regulated the invasion and migration of liver cancer.…”

Section: Markers On the Cell Surface Or Membranous Proteinsmentioning

confidence: 99%

The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma

Xiang

Yang

Pang

et al. 2016

Stem Cells International

View full text Add to dashboard Cite

Accumulating evidence suggests that hepatocellular carcinoma (HCC) is organized by liver cancer stem cells (LCSCs), which are a subset of cells with “stem-like” characteristics. Identification of the LCSCs is a fundamental and important problem in HCC research. LCSCs have been investigated by various stem cell biomarkers. There is still lack of consensus regarding the existence of a “global” marker for LCSCs in HCC. In this review article, we summarize the progress and prospects of putative biomarkers for LCSCs in the past decades, which is essential to develop future therapies targeting CSCs and to predict prognosis and curative effect of these therapies.

show abstract

Section: Markers On the Cell Surface Or Membranous Proteinsmentioning

confidence: 99%

The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma

Xiang

Yang

Pang

et al. 2016

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…[42] According to previous studies, CSCs were proven to exist in many solid tumors including glioma, melanoma, colon cancer, and hepatocellular carcinoma. [43,44] According to our knowledge, CSCs of gastric cancer were first isolated and identified in 2009 through the cell surface marker CD44. [45] Other cell surface markers of CSCs such as CD133, aldehyde dehydrogenase, CD24, and Sox2 (Sex determining Region Y-like high mobility group box-2) also have been used as diagnostic marker molecules on CSCs of gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer

Lü

Sun

et al. 2016

Medicine

View full text Add to dashboard Cite

Background:In recent years, CD44 and CD133 have been identified as 2 common used cancer stem cell (CSC) markers in gastric cancer. However, the clinicopathological and prognostic value of these markers in gastric cancer remains controversial; moreover, there is lack of comparison of these 2 markers’ roles in clinical applications. A systematic review and meta-analysis was conducted to elucidate these markers’ clinicopathological features and association with prognosis in patients with gastric cancer.Methods:Eligible studies were identified and odds ratios (ORs), hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated. Heterogeneity and sensitivity were analyzed as well. Publication bias was assessed using funnel plots and Egger tests.Results:The meta-analysis included 26 studies involving 4729 patients. High expression of CD44 was associated with Lauren type (intestinal type) (OR, 1.53 [95% CI, 1.02–2.30]; P = 0.038) and lymphatic vessel invasion (OR, 1.36 [95% CI, 1.06–1.76]; P = 0.021). CD133 overexpression was related to high TNM stage (III/IV) (OR, 3.18 [95% CI, 2.48–4.07]; P = 0.000), high depth of invasion (T3/T4) (OR, 2.97 [95% CI, 2.20–4.03]; P = 0.000), lymph node metastasis (OR, 2.82 [95% CI, 2.16–3.69]; P = 0.000), vascular invasion (OR, 6.71 [95% CI, 1.63–27.63]; P = 0.008), and distant metastasis (OR, 2.32 [95% CI, 1.64–3.29]; P = 0.000). In addition, survival analysis demonstrated a significant association between CD44, as well as CD133 and poor 5-year overall survival (HR, 1.87 [95% CI, 1.55–2.26]; P = 0.000; HR, 2.07 [95% CI, 1.76–2.44]; P = 0.000, respectively).Conclusion:These data suggest that upregulated expression of CD44 and CD133 correlates with several clinicopathological features and poor prognosis. Since the related features do not overlap, combined detection of CD44 and CD133 expression can be an especially effective tool for pathological diagnosis and prognostic prediction of gastric cancer patients in clinical applications.

show abstract

“…14,19 Liu's group reported that CD90 has a specificity of 91.9% for HCC and a sensitivity of 48.22% for predicting poor differentiation. 62 In addition, TLR4-positive CSCs were found to be significantly greater in HCC tissues with microvascular invasion and strongly associated with both early recurrence and poor patient survival. 51 Thus, high expression of these markers is significantly associated with poor response to treatment and reduced survival, and measuring and/or monitoring liver CSCs in liver lesions or the peripheral circulation may be an effective tool for surveilling growth, metastasis and relapse of HCC.…”

Section: Function Of Liver Cscs For Diagnosis and Treatment Of Hccmentioning

confidence: 99%

Hierarchical potential differentiation of liver cancer stem cells

Zhang¹,

Feng³

2017

Adv Clin Exp Med

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most malignant tumors in Chinese people and offers poor prognosis. Tumor tissue, like normal tissue, is hierarchically differentiated. Thus, minor tumor cell populations able to differentiate, such as stem cells, sustain tumor self-renewal and proliferation. The fact that liver cancer stem cells (CSCs) with different surface markers appear heterogeneous with respect to oncogenesis and drug resistance indicates that subpopulations of surface markers preserve the hierarchical potential of differentiation during proliferation, deterioration and relapse. The epithelial to mesenchymal transition (EMT) is correlated to tumor malignancy and aggression, and hepatocytes bearing EMT have obvious hierarchical differentiation potential with respect to signaling pathways such as transforming growth factor β, Wnt/β-catenin and microRNA. Therefore, it may be more effective for early diagnosis to monitor HCC recurrence using peripherally circulating CSCs, and these may also offer potential for HCC immunotherapy or for targeting HCC treatment using these markers. Thus, we reviewed the generation, hierarchical differentiation and clinical application of hepatic CSCs.

show abstract

Association Between Expression of Cancer Stem Cell Markers and Poor Differentiation of Hepatocellular Carcinoma

Cited by 31 publications

References 34 publications

The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma

The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma

Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer

Hierarchical potential differentiation of liver cancer stem cells

Contact Info

Product

Resources

About